Researchers in Colorado are advancing injectable and biomaterial-based therapies that, in animal studies, restored damaged cartilage and bone by triggering the body’s own repair processes, potentially offering a minimally invasive alternative to...
Mesoblast said its 300-patient placebo-controlled Phase 3 study of rexlemestrocel-L for chronic low back pain remains on track, with top-line data expected in mid-2027 to support a planned FDA filing for the...
Regeneron said it will reduce Medicaid and future U.S. drug prices in line with other developed countries, enable direct discounted purchases of Praluent through TrumpRx.gov, and continue investing in domestic R&D and...
The recommendation is backed by Phase III data showing that Novartis’ one-time gene therapy improved motor function in people aged two and older with SMA and could lessen reliance on ongoing chronic...
Mesoblast has secured exclusive global rights to a CAR technology platform to engineer its MSC therapies for more precise targeting and greater potency in inflammatory and autoimmune diseases, including bowel disease and...
This marks Taiwan’s first GMP facility with mRNA and nucleic acid manufacturing capabilities to expand its CRDMO services and support advanced therapies from development through commercial production.
Orthocell has gained approval for its Remplir nerve repair device across U.S. Department of Defence and Veterans Affairs hospital networks, expanding access to more than 220 military and veteran care facilities as...
Gallant said its pilot study found that intravenous stem cell therapy significantly improved pain and quality of life in cats with osteoarthritis versus placebo, supporting a faster regulatory route as the company...
The Geneva site upgrade will expand Bracco’s GMP production capacity for its microbubble-based cell selection and activation platform, aiming to simplify cell therapy manufacturing and support clinical availability by mid-2027.
The Phase II study will test XellSmart’s iPSC-derived off-the-shelf cell therapy in 30 Parkinson’s patients after Phase I showed meaningful motor and quality-of-life gains with no transplant-related adverse events.
